LEGN

AI Memo

Legend Biotech

As of 2026-09-12/Confidence medium/Horizon 6‑12m

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-09-12 • Model: RankAlpha Sentiment Codex

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

—

Confidence

medium

Horizon

6‑12m

Key catalyst

September IMS data will test CARVYKTI durability and real-world safety • 2026-09-25

Base target: $25 / p=50% prob

Biggest risk

The thesis remains concentrated in one partnered franchise with serious labeled safety risks. LB2501 evidence is based on only six higher-dose patients with limited follow-up, a recent CEO transition adds execution uncertainty, and the June equity offering demonstrates continued dilution risk despite a stronger balance sheet.

Invalidation

Break below $13 or thesis failure.

What would change my mind?

CARVYKTI growth, broader global availability, and improving collaboration economics produced Legend's first profitable quarter, while the IMS evidence cycle and early LB2501 proof-of-concept offer additional clinical upside. Maintaining adjusted profitability through the second half would represent a material de-risking of the operating model.

Research note

Recommendation

—

Confidence

medium

As of

2026-09-12

Base target

$25

p=50%

Bull target

$35

p=25%

Bear target

$13

p=25%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

The next earnings update must confirm that the first profitable quarter is repeatable
LB2501 follow-up could validate or weaken the in vivo CAR-T platform thesis
CARVYKTI growth, broader global availability, and improving collaboration economics produced Legend's first profitable quarter, while the IMS evidence cycle and early LB2501 proof-of-concept offer additional clinical upside.

BearKey bullets

CARVYKTI carries serious safety risks including cytokine release syndrome, neurologic toxicities, cytopenias, infections, enterocolitis, and secondary malignancies; unfavorable real-world safety evidence could constrain earlier-line adoption.
Commercial and financial performance remains highly dependent on CARVYKTI and execution under the Janssen collaboration.
LB2501's initial efficacy signal comes from six higher-dose patients with short follow-up and may not remain durable or reproducible in a larger population.

WatchKey bullets

September IMS data will test CARVYKTI durability and real-world safety

Summary

High-level snapshot

Recommendation

Model confidence

medium

Timeframe

6‑12m

Asset

Equity

Trigger

Base case: $25 (p=50%)

Target spread vs base: +40% / -48%

Scenario probabilities

Bull Target: $35 (p=25%)Base Target: $25 (p=50%)Bear Target: $13 (p=25%)

Commentary

Official Legend investor-relations releases verify the constructive operating and clinical tone: Q2 delivered 50% CARVYKTI net-trade-sales growth, positive operating income and adjusted net income, while the September IMS program creates a specific near-term evidence checkpoint. However, verified analyst revisions, options data, short interest, sufficient social coverage, and a clean post-earnings market-reaction attribution remain unavailable; the sharp gap between the anchor and a target lacking a documented analyst count should not be treated as positive evidence. Confidence therefore remains moderate and monitoring-oriented.

As of 2026-09-12 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

Bear Case

Drivers

Scannable catalysts and supporting factors

The next earnings update must confirm that the first profitable quarter is repeatable
LB2501 follow-up could validate or weaken the in vivo CAR-T platform thesis

Scenarios

Bull Target (Scenario probability)

$35 / p=25% prob

Base Target (Scenario probability)

$25 / p=50% prob

Bear Target (Scenario probability)

$13 / p=25% prob

Analysis 2026-09-12 · RankAlpha Sentiment Codex

Analysis reference price unavailable. Targets are shown without scenario returns.

Sentiment & Exposure

News Sentiment (30d)

0.25

Social Sentiment (7d)

0.00

Events

Other notable items detected

EVENT2026-09-25
September IMS data will test CARVYKTI durability and real-world safety
Legend scheduled updated CARTITUDE-2 Cohort A follow-up, including at least five-year remission and survival data, for September 25, alongside real-world outcomes and post-authorization safety findings during the September 23-26 IMS meeting. Durable earlier-line efficacy would support adoption, while the safety evidence is particularly important given CARVYKTI's boxed warnings. [#IR-2026-09-10]
Prob 95.00% • Move 7.00% • Priced-in 55.00%

Short-term Catalysts

Next few weeks

The next earnings update must confirm that the first profitable quarter is repeatable
2026-11-15
Q2 CARVYKTI net trade sales rose 50% year over year to approximately $657 million, availability expanded to 348 sites in 19 markets, operating income reached $57.7 million, and adjusted net income reached $63.1 million. Management said it expected adjusted-net-income profitability through the second half of 2026, making the next quarterly report an important operating-leverage test. [#IR-2026-08-11] [#PR-EARNINGS-2026-08-12]
Prob 70% • Move 12% • Priced-in 45%

Long-term Catalysts

Months to a year

LB2501 follow-up could validate or weaken the in vivo CAR-T platform thesis
2027-06-30
Initial Phase 1 LB2501 results showed a 100% objective response rate and 83.3% complete-response rate among six patients at the higher dose, without lymphodepletion; however, follow-up was short and the sample was very small. Additional patients and longer durability and safety follow-up are required before assigning substantial platform value. [#IR-2026-06-14] [#IR-2026-08-11]
Prob 55% • Move 18% • Priced-in 30%

Risks

CARVYKTI carries serious safety risks including cytokine release syndrome, neurologic toxicities, cytopenias, infections, enterocolitis, and secondary malignancies; unfavorable real-world safety evidence could constrain earlier-line adoption.
Commercial and financial performance remains highly dependent on CARVYKTI and execution under the Janssen collaboration.
LB2501's initial efficacy signal comes from six higher-dose patients with short follow-up and may not remain durable or reproducible in a larger population.
Legend raised approximately $212 million through a 7.7-million-ADS offering, strengthening liquidity but highlighting shareholder-dilution risk.
The final outcome of negotiations with the Chinese Tax Authority could produce a materially different tax liability from management's current estimate.
The interim CEO transition creates leadership and execution risk even though management characterized it as continuity rather than a strategy change.

Peers

Symbol	Summary
GILD	Gilead is the most relevant supplied benchmark because Kite provides commercial cell-therapy exposure and manufacturing experience, but Gilead's diversified portfolio makes direct valuation comparison weak.
AMGN	Amgen is a broad biotechnology benchmark rather than a direct CAR-T peer. Its scale and diversification help frame the discount associated with Legend's concentrated CARVYKTI exposure, but not a precise multiple.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment Codex
Analysis date: 2026-09-12

Loading AI feed…

Symbol

Summary

GILD

Gilead is the most relevant supplied benchmark because Kite provides commercial cell-therapy exposure and manufacturing experience, but Gilead's diversified portfolio makes direct valuation comparison weak.

AMGN

Amgen is a broad biotechnology benchmark rather than a direct CAR-T peer. Its scale and diversification help frame the discount associated with Legend's concentrated CARVYKTI exposure, but not a precise multiple.